Clinical response and long-term follow-up of 20 patients with refractory solar urticaria under treatment with omalizumab

Morgado‐Carrasco, Daniel; Weth, Macarena Giacaman-von der; Fustà‐Novell, Xavier; Podlipnik, Sebastián; Pérez‐Ferriols, A.; Aguilera, Paula

doi:10.1016/j.jaad.2019.05.070

Cited by 10 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, this study gives value to the role of omalizumab when failure to antihistamines occur. These results are in line with previously published studies ( 27 , 28 ), highlighting that partial/total control with omalizumab may be achieved relatively rapidly after initiation of therapy. It is important to note that the initiation of omalizumab was accompanied by a sharp decrease in the use of antihistamines after 6 months of treatment, which further reveals the clinical benefits of omalizumab.…”

Section: Discussionsupporting

confidence: 92%

“…It has been proposed that patients with presence of CIndU have a lower probability of remission and, thus, a longer need for omalizumab treatment, which can explain longer drug survival related to well-controlled disease activity ( 30 ), as also seen our case. Furthermore, it is important to enhance the therapeutic difficulty linked to the loss of clinical improvement when omalizumab is stopped ( 8 , 28 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Solar Urticaria: An Ambispective Study in a Long-term Follow-up Cohort with Emphasis on Therapeutic Predictors and Outcomes

Pesqué,

Ciudad,

Andrades

et al. 2024

Acta Derm Venereol

View full text Add to dashboard Cite

Solar urticaria is a rare photodermatosis with several unknown pathogenic, clinical and therapeutic aspects. This study analysed the clinical and therapeutic features of a long-term follow-up solar urticaria cohort, with a focus on omalizumab management and outcomes, and characterized omalizumab response with the use of the high-affinity immunoglobulin E (IgE) receptor (FcεRI) and the Urticaria Control Test. An observational, unicentric, ambispective study was conducted from 2007 to 2023. Solar urticaria was diagnosed in 41 patients with a median follow-up of 60 months. Thirteen patients were prescribed omalizumab, with a median treatment time of 48 months. A significant decrease in FcεRI baseline levels and subsequent median increase in Urticaria Control Test was evidenced after omalizumab prescription in all patients. Drug survival at 48 months was at 88.9%. Omalizumab stepping-down protocol led to sustained omalizumab discontinuation in only 1 patient. Median basal Urticaria Control Test was lower (p < 0.01) in patients who were prescribed omalizumab and in patients without remission. This study contributes to our knowledge of omalizumab outcomes in real-life clinical practice and highlights the pathogenic importance of IgE-mediated pathways in solar urticaria, where FcεRI emerges as a possible biomarker of omalizumab response.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Solar Urticaria: An Ambispective Study in a Long-term Follow-up Cohort with Emphasis on Therapeutic Predictors and Outcomes

Pesqué,

Ciudad,

Andrades

et al. 2024

Acta Derm Venereol

View full text Add to dashboard Cite

show abstract

“…We retrieved two cohort studies 24,25 and eight cross-sectional studies 11,[26][27][28][29][30][31][32] (Table 2). The difference of clinical response (CR) rate…”

Section: The Efficacy and Safety Of Omalizumab For Cindu In Observati...mentioning

confidence: 99%

Comparison between chronic spontaneous urticaria and chronic induced urticaria on the efficacy of omalizumab treatment: A systematic review and meta‐analysis

Qiu

Huang

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

This meta-analysis aimed to assess the efficacy of omalizumab in the treatment of refractory-to-antihistamines chronic induced urticaria (CIndU) in comparison with that of refractory-to-antihistamines chronic spontaneous urticaria (CSU). We retrieved interventional studies and observational studies on omalizumab efficacy to CIndU patients and efficacy comparison between CSU and CIndU both refractory to H1-antihistamines in electronic databases (accessed till May 2022). The odd ratio (OR) and 95% confidence interval (CI) was calculated with a random-effect model in this meta-analysis. The majority of patients with different CIndU subtypes gained complete or partial response and good safety after omalizumab treatment. A total of five studies with 355 CSU patients and 103 CIndU patients were included for the meta-analysis. There was no significant difference in the efficacy of omalizumab in the treatment of CSU and CIndU (OR -0.83, 95% CI [0.84, 2.21], P > 0.05). Based on the validity of omalizumab in the treatment of various CIndU subtypes and nondifferential efficacy between CSU and CIndU, it is reasonable to list omalizumab as a third-line treatment of refractory CIndU.

show abstract

Cutaneous Photosensitivity Diseases

Ibbotson

2024

Rook's Textbook of Dermatology

View full text Add to dashboard Cite

The photodermatoses are a diverse group of conditions in which abnormal responses to light exposure are the hallmark. Photodiagnostic investigations through a specialist unit may be essential to ensure accurate diagnosis and management, and this chapter explores the nature of the photodermatoses and the photodiagnostic techniques that can be applied. Management approaches include early diagnosis, prevention and disease suppression, and awareness of the significant adverse impact on well‐being and psychological health that can occur with photosensitivity. Photoprotection is a mainstay approach for the photodermatoses but is often not sufficient alone for disease control. Desensitisation through natural hardening or light‐based therapies may be feasible, although systemic immunosuppressants and immunomodulators may be required. Awareness of the possibility of vitamin D deficiency is also necessary. This chapter will cover these approaches in detail.

show abstract

Clinical response and long-term follow-up of 20 patients with refractory solar urticaria under treatment with omalizumab

Cited by 10 publications

References 5 publications

Solar Urticaria: An Ambispective Study in a Long-term Follow-up Cohort with Emphasis on Therapeutic Predictors and Outcomes

Solar Urticaria: An Ambispective Study in a Long-term Follow-up Cohort with Emphasis on Therapeutic Predictors and Outcomes

Comparison between chronic spontaneous urticaria and chronic induced urticaria on the efficacy of omalizumab treatment: A systematic review and meta‐analysis

Cutaneous Photosensitivity Diseases

Contact Info

Product

Resources

About